Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 6/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 3/20 | 0.33 |
| ▸ | NMT1 | P30419 | 3/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23106135 | 0.88 | FURIN (0.36) | FURINNPY1RAKT1CTSLNMT2 | |
| SCHEMBL23106266 | 0.88 | FURIN (0.36) | FURINNPY1RAKT1CTSLNMT2 | |
| SCHEMBL30831346 | 0.84 | FURIN (0.38) | FURINNPY1RCHRNA1CHRNGCHRNB1 | |
| SCHEMBL23106051 | 0.82 | FURIN (0.36) | FURINNPY1RNMT2NMT1CTDSP1 | |
| SCHEMBL23106090 | 0.80 | NMT2 (0.37) | FURINNPY1RCTSLNMT2NMT1 | |
| SCHEMBL22184192 | 0.79 | SHMT1 (0.42) | FURINNPY1RAKT1SHMT1CTDSP1 | |
| Bicarbonate SCHEMBL30831304 | 0.79 | PDF (0.41) | FURINLMNAKMT2A | |
| SCHEMBL17860166 | 0.78 | FURIN (0.38) | FURINPOLB | |
| SCHEMBL19776894 | 0.78 | FURIN (0.38) | FURINPOLB | |
| SCHEMBL23106146 | 0.78 | FURIN (0.36) | FURINCHRNA1CHRNGCHRNB1CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | FURIN 1194/4885NPY1R 2878/4885AKT1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.